KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is making waves in the biotechnology sector, drawing significant attention from investors with its promising pipeline and remarkable potential upside. With a market capitalization of $764.26 million, this U.S.-based biopharmaceutical company is laser-focused on addressing unmet medical needs, particularly through the development of innovative therapies for hereditary angioedema (HAE).

**Strategic Focus on HAE**

KalVista’s flagship product candidate, EKTERLY, is a testament to its commitment to combatting HAE. This condition, characterized by recurrent swelling episodes, represents a significant challenge for both patients and healthcare providers. EKTERLY, a small molecule plasma…